Tag: USA

Italian pharmaceutical group Angelini Pharma has agreed to acquire Catalyst Pharmaceuticals in an all-cash transaction valued at $4.1bn. The acquisition marks a pivotal expansion for the privately held European drugmaker, establishing its first direct commercial footprint in the United States while bolstering its central nervous system and rare disease portfolio. The transaction is expected to close in the third quarter…

Listed American biopharmaceutical company Gilead Sciences has entered into a definitive agreement to acquire Tubulis, a privately held German biotechnology company, for a total potential consideration of $5bn. Under the terms of the deal, Gilead will provide an upfront cash payment of $3.15bn, with an additional $1.85bn tied to future contingent milestones. The transaction is expected to close in the…

Boston Scientific Corporation has entered into a definitive agreement to acquire Penumbra in a transaction valued at approximately $14.5bn. The American biotechnology and biomedical engineering firm and multinational manufacturer of medical devices announced it was buying California-based medical device company Penumbra on January 15. For operators and investors, the deal represents a significant pivot for Boston Scientific as it seeks…

UK–listed digital mental-health specialist Kooth, best known for its youth platform Soluna, has agreed to acquire US start-up Kismet Health adding a purpose-built teletherapy solution for children aged 5-12 and expanding its addressable market across American Medicaid and school-funded programs. The deal underscores investors’ growing appetite for scalable, tech-enabled behavioural health models that can penetrate underserved geographies and younger cohorts.…

British multinational Smith & Nephew’s decision to base Chief Financial Officer John Rogers in the United States marks more than a change of address; it underscores the medical-technology group’s growing American centre of gravity and re-ignites debate over a potential shift of the company’s corporate and listing domicile. Rogers has been employed in the U.S. since September 29, after spending…

Global biopharmaceutical company AstraZeneca has announced a $50 billion investment in the United States by 2030 to expand its pharmaceutical manufacturing and R&D footprint. The initiative, unveiled on July 22, 2025, includes a proposed multi-billion-dollar manufacturing facility in Virginia focused on chronic disease treatments such as oral GLP-1s, baxdrostat for hypertension, and PCSK9 inhibitors, which will be the company’s largest single-site investment globally. This expansion…